Crinetics Pharmaceuticals Inc (NAS:CRNX)
$ 57.67 0.9 (1.59%) Market Cap: 5.35 Bil Enterprise Value: 4.54 Bil PE Ratio: 0 PB Ratio: 5.60 GF Score: 39/100

Crinetics Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 11:00PM GMT
Release Date Price: $25.38 (+0.51%)
Jessica Macomber Fye
JP Morgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm one of the biotech analysts at JPMorgan. And we're continuing the 2020 Healthcare Conference today with Crinetics. We are going to do a Q&A session with the management team right after this, just down the hall in the Sussex Room. And for the presentation, let me turn it over to the company's CEO, Scott Struthers.

R. Scott Struthers
Crinetics Pharmaceuticals, Inc. - Founder, President, CEO & Director

Thanks, Jess, and thanks for the invite. Hello, everybody. Thanks for coming today. I'd like to tell you a bit of an update about the company. There's a pretty data-rich website -- deck on our website, so I'd encourage you to go there if you want to see more details, but I'll kind of skip through some of the highlights here today. And I think the thing to know about us at Crinetics is we're really trying to build something special that can bring new drugs to patients around the world in the area of endocrinology and endocrine

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot